FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder - FDA.gov
fda.govSubmitted by fdagov3951 in business
The FDA approved Adzynma indicated for prophylactic or on demand enzyme replacement therapy in patients with congenital thrombotic thrombocytopenic purpura.